Cytokines and smooth muscle cells in atherosclerosis

Cardiovascular Research

Volumn 27, Issue 7, 1993, Pages 1184-1190

  Nilsson, Jan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER;

ARTERIOSCLEROSIS; CYTOKINES; HUMAN; LIPID PEROXIDATION; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR;

EID: 0027240295     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1093/cvr/27.7.1184     Document Type: Article

References (94)

1. Faggiotto A, Ross R, Harker L. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis 1984;4:323-40.
2. Walker L, Reidy M, Bowyer D. Morphology and cell kinetics of fatty streak lesion formation in the hypercholesterolemic rabbit. Am J Pathol 1986;126:450-9.
3. Gerrity R. The role of monocytes in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty streaks. Am J Pathol 1981;103:181-90.
4. Masuda J, Ross R. Atherogenesis during low level hypercholesterolemia in the non-human primate. I. Fatty streak formation. Arteriosclerosis 1990;10:164-77.
5. Faggiotto A, Ross R. Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. Arteriosclerosis 1984;4:341-56.
6. Masuda J, Ross R. Atherogenesis during low level hypercholesterolemia in the non-human primate. II. Fatty streak conversion to fibrous plaque. Arteriosclerosis 1990;10:178-87.
7. Thyberg J, Palmberg L, Nilsson J, Ksiazek T, Sjölund M. Phenotype modulation in primary cultures of arterial smooth muscle cells. On the role of platelet-derived growth factor. Differentiation 1983;23:156-67.
8. Campbell GR, Campbell JH. Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis. Exp Mol Pathol 1985;42:139-62.
9. Thyberg J, Nilsson J, Palmberg L, Sjölund M. Adult human arterial smooth muscle cells in primary culture. Modulation from contractile to synthetic phenotype. Cell Tissue Res 1985;239: 69-74.
10. Nilsson J. Growth factors and the pathogenesis of atherosclerosis. Atherosclerosis 1986;62:185-99.
11. Aqel NM, Ball RY, Waldman H, Mitchinson MJ. Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis 1984;53:197-204.
12. Aqel NM, Ball RY, Waldmann H, Mitchinson MJ. Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies. J Pathol 1985;146:197-204.
13. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986;6: 131-8.
14. Gown AM, Tsukada T, Ross R. Human atherosclerosis II: immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol 1986;125:191-207.
15. Munro JM, van der Walt JD, Munro CS, Chalmers J AC, Cox EL. An immunohistochemical analysis of human aortic fatty streaks. Human Pathol 1987;18:375-80.
16. Hansson G, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989;135:169-75.
17. Hemler ME, Glass D, Coblyn JS, Jacobson JG. Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation. J Clin Invest 1986;78:696-702.
18. Hansson GK Jonasson L, Holm J, Claesson-Welsh L. Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ, and the invariant gamma chain. Clin Exp Immunol 1986;64:261-8.
19. Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989;9:567-78.
20. Klareskog L, Forsum U, Scheynius A, Kabelitz D, Wigzell H. Evidence in support of a self-perpetuating HLA-DR dependent delayed type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci USA 1982;79:3632-6.
21. Hanafusa T, Chiovato L, Doniach D, Pujol-Burrel R, Russell RCG, Bottazzo GF. Abberant expression of HLA-DR antigen on thyrocytes in Graves’ disease: relevance for autoimmunity. Lancet 1983;ii:1111-5.
22. Dinarello CA. An update on human interleukin-1 from molecular biology to clinical relevance. J Clin Immunol 1985;5:287-97.
23. Libby P, Ordovas JM, Birinyi LK, Auger KR, Dinarello CA. Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest 1986;78:1432-8.
24. Raines E, Dower S, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 1989;243:393-6.
25. Ikeda U, Ikeda M, Oohara T, Kano S, Yaginuma T. Mitogenic action of interleukin-1 alfa on vascular smooth muscle cells mediated by PDGF. Atherosclerosis 1990;84:183-8.
26. Bejeck BE, Li DY, Deuel TF. Transformation by v-sis occurs by an internal autoactivation mechanism. Science 1989;245: 1496-9.
27. Bejeck BE, Hoffman RM, Lipps D, et al. The v-sis oncogene product but not platelet-derived growth factor (PDGF) A homodimers activate PDGF alpha and beta receptors intracellularly and initiate cellular transformation. J Biol Chem 1992;267:3289-93.
28. Gay C, Winkles J. Interleukin 1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells. Proc Natl Acad Sci USA 1991;88:296-300.
29. Sawada H, Kan M, McKeehan W. Opposite effects of monokines (interleukin-1 and tumor necrosis factor) on proliferation and heparin-binding (fibroblast) growth factor binding to human aortic endothelial and smooth muscle cells. In Vitro Cell Dev Biol 1990;26:213-6.
30. Nomoto A, Mutoh S, Hagihara H, Yamaguchi I. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis 1988;72:213-9.
31. Beasley D, Cohen R, Levinsky N. Interleukin 1 inhibits contraction of vascular smooth muscle. J Clin Invest 1989; 83:331-5.
32. Busse R, Mülsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990; 275:87-90.
33. French J, Lambert L, Dage R. Nitric oxide synthase inhibitors inhibit interleukin-1-β-induced depression of vascular smooth muscle. J Pharmacol Exp Ther 1991;259:260-4.
34. Schini V, Junquera D, Scott-Burden T, Vanhoutte P. Interleukin-1 β induces the production of an L-arginine-derived relaxing factor from cultured smooth muscle cells from rat aorta. Biochem Biophys Res Commun 1991;176:114-21.
35. Clinton S, Fleet J, Loppnow H, et al. Interleukin-1 gene expression in rabbit vascular tissue in vivo. Am J Pathol 1991;138:1005-14.
36. Warner S, Auger K, Libby P. Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J Exp Med 1987;165:1316-31.
37. Lopponow H, Libby P. Proliferation or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest 1990;85:731-8.
38. Norioka K-I, Hara M, Harigai M, et al. Pretreatment of human vascular smooth muscle cells with interleukin-1 enhances interleukin-6 production and cell proliferation (action of IL-1 on vascular smooth muscle cells). Autoimmunity 1991;7:41-50.
39. Billiiau A. Interferon beta-2 as a promoter and differentiation of B cells. Immunol Today 1987;8:84-7.
40. Wang J, Sica A, Peri G, et al. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arteriosclerosis Thromb 1991;11:1166-74.
41. Baggiolini M, Waltz A, Kunkel SL. Neutrophil-activating protein-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989;84:1045-9.
42. Gimbrone MA, Obin MS, Brock AF, et al. Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. Science 1989;246:1601-3.
43. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 1990;11:97-101.
44. Nelken N, Coughlin S, Gordon D, Wilcox J. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88:1121-7.
45. Trinchieri G, Perussia B. Immune interferon: a pleitropic lymph-okine with multiple effects. Immunol Today 1985;6:131-5.
46. Hansson G, Jonasson L, Holm J, Clowes M, Clowes A. Gamma-interferon regulates vascular smooth muscle proliferation and la antigen expression in vivo and in vitro. Circ Res 1989; 63:712-9.
47. Amento E, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arteriosclerosis Thromb 1991;11:1223-30.
48. Warner S, Friedman G, Libby P. Immune interferon inhibits proliferation and induces 2’-5’-oligoadenylate synthetase gene expression in human vascular smooth muscle cells. J Clin Invest 1989;83:1174-82.
49. Hansson GK, Hellstrand M, Rymo L, Rubbia L, Gabbiani G. Interferon gamma inhibits both proliferation and expression of alpha smooth muscle actin in arterial smooth muscle cells. J Exp Med 1989;170:1595-608.
50. Hansson GK, Holm J. Interferon gamma inhibits arterial stenosis after injury. Circulation 1991;84:1266-72.
51. Hansson G, Holm J, Holm S, et al. T lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci USA 1991; 88:10530-4.
52. Ferns GAA, Reidy MA, Ross R. Balloon catheter de-endothelialization of the nude rat carotid. Response to injury in the absence of functional T lymphocytes. Am J Pathol 1991;138: 1045-57.
53. Wilson AC, Schaub RG, Goldstein RC, Kuo P. Suppression of aortic atherosclerosis in cholesterol-fed rabbits by purified rabbit interferon. Arteriosclerosis 1990;10:208-14.
54. Beutler B, Cerami A. Cachectic and tumor necrosis factor as two sides of the same biological coin. Nature 1985;320:584-8.
55. Warner SJC, Libby P. Human smooth muscle cells. Target and source of tumor necrosis factor. J Immunol 1989;142:100-9.
56. Barath P, Fishbein M, Cao J, Berenson J, Helfant R, Forrester J. Tumor necrosis factor gene expression in human vascular intimal smooth muscle cells detected by in situ hybridization. Am J Pathol 1990:137:503-9.
57. Hollenberg S, Cunnion R, Parrillo J. The effect of tumor necrosis factor on vascular smooth muscle. In vitro studies using rat aortic rings. Chest 1991;100:1133-7.
58. Soff G, Jackman R, Rosenberg R. Expression of thrombomodulin by smooth muscle cells in culture: different effects of tumor necrosis factor and cyclic adenosine monophosphate on thrombomodulin expression by endothelial cells and smooth muscle cells in culture. Blood 1991;77:515-8.
59. Cornelius P, Enerbäck S, Bjursell G, Olivecrona T. Regulation of lipoprotein lipase mRNA content in 3T3-LI cells by tumor necrosis factor. Biochem J 1986:249:765-9.
60. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B. Some recent advances in the chemistry and biology of transforming growth factor beta. J Cell Biol 1987:105:1039-45.
61. Battegay E, Raines E, Seifert R, Bowen-Pope D, Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990;63: 515-24.
62. Hahn A, Resink T, Bernhardt J, Ferracin F, Bühler F. Stimulation of autocrine platelet-derived growth factor AA-homodimer and transforming growth factor β in vascular smooth muscle cells. Biochem Biophys Res Commun 1991;178:1451-8.
63. 1, during repair of arterial injury. J Clin Invest 1991;88:904-10.
64. Hadrava V, Kruppa U, Russo R, Lacourcière Y, Tremblay J, Hamet P. Vascular smooth muscle cell proliferation and its therapeutic modulation in hypertension. Am Heart J 1991;122:1198-203.
65. 1, expression and effect in aortic smooth muscle cells from spontaneously hypertensive rats. Hypertension 1991; 17: 896-901.
66. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986;46:155-69.
67. Burgess WH, Maciag T. The heparin-binding family of growth factors. Annu Rev Biochem 1989;58:575-606.
68. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991;251:936-9.
69. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-25.
70. Brown MS, Basu SK, Falck JR, Ho YK, Goldstein JL. The scavenger cell pathway for lipoprotein degradation. Specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages. J Supramol Struct 1980;13:67-81.
71. Sparrow CP, Parthasarathy S, Steinberg D. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem 1988;264:2599-604.
72. Arai H, Kita T, Yokode M, Narumiya S, Kawai C. Multiple receptors for modified low density lipoproteins in mouse peritoneal macrophages: different uptake mechanisms for acetylated and oxidized low density lipoproteins. Biochem Biophys Res Commun 1989;159:1375-82.
73. Kodama T, Freeman M, Rohrer L, Zabricky J, Matsudaira P, Krieger M. Type I macrophage scavenger receptor contains a-helical and collagen-like coiled coils. Nature 1990;343:531-5.
74. Freeman M, Ashkenas J, Rees DJG, et al. An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors. Proc Natl Acad Sci USA 1990;87:8810-4.
75. Morel DW, DiCorleto PE, Chisolm GM. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 1984;4:357-64.
76. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984;83:3883-7.
77. Cathcart MK, Morel DW, Chisholm GM. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J Leucocyt Biol 1987;38:341-50.
78. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipemic rabbits. Science 1988;241:215-8.
79. Palinsky W, Rosenfeld ME, Ylä-Herttuala et al. Low density lipoprotein undergoes modification in vivo. Proc Natl Acad Sci USA 1989;86:1372-6.
80. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyper-lipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987;84:5928-31.
81. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effects of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic (WHHL) rabbit. Proc Natl Acad Sci USA 1987;84:7725-9.
82. Hessler JR, Robertson AL, Chisholm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979;32:213-29.
83. Berliner JA, Territo MC, Sevanian A. et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990;85:1260-6.
84. Frostegård J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified low density lipoprotein increases the adhesive properties of endothelial cells. Atherosclerosis 1991:90:119-26.
85. Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony stimulating factor by modified low density lipoproteins. Nature 1990;344:254-7.
86. Fox PL, DiCorleto PE. Modified low density lipoproteins suppress production of a platelet-derived growth factor-like protein by cultured endothelial cells. Proc Natl Acad Sci USA I986;83: 4774-8.
87. Fox PL, DiCorleto PE. Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein. Science 1988:249: 453-6.
88. Quinn MT, Parthasarathy S, Fong LG, Steiberg D. Oxidatively modified low density lipoprotein: a potential role in recruitment and retention of monocytes/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987:84:2995-8.
89. Frostegård J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U 937. Proc Natl Acad Sci USA 1990:87:904-8.
90. Frostegård J. Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Induction of T cell activation by oxidized low density lipoprotein. Arteriosclerosis Thromb 1992;12:461-7.
91. Malden LT, Chain A, Raines EW, Ross R. The influence of oxidatively modified low density lipoproteins on expression of platelet derived growth factor in human monocyte-derived macrophages. J Biol Chem 1991;266:13901-7.
92. Hamilton TA, Ma GP, Chisholm GM. Oxidized low density lipoprotein suppresses the expression of tumor necrosis factor alpha mRNA in stimulated murine perotoneal macrophages. J Immunol 1990;144:2343-50.
93. Riemersma RA, Wood DA, MacIntyre CCA, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet 1991;337:1-5.
94. Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to low density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992;339:1183-6.